Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden.
Department of Internal Medicine and Emergency Medicine, Skåne University Hospital, Malmö, Sweden.
Sci Rep. 2019 Apr 4;9(1):5609. doi: 10.1038/s41598-019-42154-5.
Long follow up is needed in prospective cohort study evaluation of plasma biomarkers for incident peripheral arterial disease (PAD) Middle-aged PAD-free individuals from the cardiovascular cohort of the Malmö Diet and Cancer study (n = 5550; 1991-94) were followed prospectively for a median time of 23.4 years. The plasma biomarkers lipoprotein-associated phospholipase A2 (Lp-PLA) activity and mass, proneurotensin, and CRP, were studied in relation to incidence of PAD until December 31, 2016. The diagnosis of PAD could be validated and confirmed in 98%. Cox regression was used to calculate hazard ratios (HR) per 1 standard deviation increment of each respective log transformed plasma biomarker. Cumulative incidence of PAD was 4.4% (men 5.9%, women 3.3%). Adjusting for age, gender, smoking, body mass index, hypertension, diabetes mellitus, Lp-PLA activity (HR 1.33; 95% CI 1.17-1.52), Lp-PLA mass (HR 1.20; 95% CI 1.05-1.37) and CRP (HR 1.55; 95% CI 1.36-1.76) remained independently associated with incident PAD. The plasma biomarkers Lp-PLA activity and mass, and CRP were markers of PAD risk, implying that they might be useful biomarkers for subclinical atherosclerosis and atherosclerotic disease.
在评估血浆生物标志物与新发外周动脉疾病（PAD）的前瞻性队列研究中需要进行长期随访。来自马尔默饮食与癌症研究心血管队列的中年无 PAD 个体（n=5550；1991-94 年）前瞻性随访中位时间为 23.4 年。研究了脂蛋白相关磷脂酶 A2（Lp-PLA）活性和质量、前神经降压素和 CRP 与 PAD 发病的关系，直至 2016 年 12 月 31 日。PAD 的诊断可在 98%的情况下进行验证和确认。使用 Cox 回归计算每个相应对数转换血浆生物标志物每 1 个标准差增量的风险比（HR）。PAD 的累积发病率为 4.4%（男性 5.9%，女性 3.3%）。在校正年龄、性别、吸烟、体重指数、高血压、糖尿病、Lp-PLA 活性（HR 1.33；95%CI 1.17-1.52）、Lp-PLA 质量（HR 1.20；95%CI 1.05-1.37）和 CRP（HR 1.55；95%CI 1.36-1.76）后，它们仍然与 PAD 的发生独立相关。Lp-PLA 活性和质量以及 CRP 是 PAD 风险的标志物，这意味着它们可能是亚临床动脉粥样硬化和动脉粥样硬化疾病的有用生物标志物。
